Ardelyx, Inc. (ARDX)
| Market Cap | 824.81M -34.9% |
| Revenue (ttm) | 450.89M +16.8% |
| Net Income | -55.70M |
| EPS | -0.23 |
| Shares Out | 249.19M |
| PE Ratio | n/a |
| Forward PE | 132.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,816,284 |
| Open | 3.390 |
| Previous Close | 3.390 |
| Day's Range | 3.230 - 3.408 |
| 52-Week Range | 3.230 - 8.400 |
| Beta | 0.68 |
| Analysts | Strong Buy |
| Price Target | 12.90 (+289.73%) |
| Est. Earnings | Oct 29, 2026 |
About ARDX
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 an... [Read more]
Financial Performance
In 2025, Ardelyx's revenue was $407.32 million, an increase of 22.09% compared to the previous year's $333.62 million. Losses were -$61.60 million, 57.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price target is $12.9, which is an increase of 289.73% from the latest price.
News
Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026
Presentations include real-world XPHOZAH® (tenapanor) data and new insights into hyperphosphatemia management and outcomes Presentations include real-world XPHOZAH® (tenapanor) data and new insights i...
Kaplan Fox Reminds Ardelyx, Inc. (ARDX) Investors with Significant Losses to Seek a Leadership Role Before Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: AR...
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Ardelyx, Inc. (ARDX)
Philadelphia, Pennsylvania--(Newsfile Corp. - October 1, 2026) - What is The Investigation About? Grabar Law Office is investigating whether certain officers and directors of Ardelyx, Inc. (NYSE: ARDX...
Robbins LLP is Investigating Allegations that Ardelyx, Inc. Misled Investors Regarding the True State of the Company's Commercial Performance and Growth Prospects for its Two Core Drug Products
San Diego, California--(Newsfile Corp. - September 30, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased o...
Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards
Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the Year Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative,...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDX
Ardelyx's Chief Commercial Officer, Eric Foster, is named as an individual defendant in a securities class action alleging he assured investors the Company's patient-access strategy was working while ...
Ardelyx Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong demand for IBSRELA and XPHOZAH drives robust revenue growth, with profitability expected in 2027 and IP protection to 2042. Strategic focus includes expanding indications, optimizing specialty pharmacy distribution, and disciplined capital allocation. The company is set for sustained cash generation, minimal dilution, and multiple product launches by decade's end.
Ardelyx management to meet with Piper Sandler
Meeting to be held on September 16 hosted by Piper Sandler.
Ardelyx Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Profitability is targeted for 2027, with strong growth in IBSRELA and XPHOZAH and a disciplined approach to payer contracting and capital allocation. Market access initiatives, robust IP, and pipeline expansion support long-term growth, while business development focuses on early-stage assets.
Ardelyx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercializati...
Ardelyx price target lowered to $15 from $16 at Piper Sandler
Piper Sandler lowered the firm’s price target on Ardelyx (ARDX) to $15 from $16 and keeps an Overweight rating on the shares. With Q2 2026 reporting wrapped up, the firm…
ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx
Ardelyx cut its 2026 IBSRELA revenue guidance by up to $80 million on August 6, 2026, citing payer utilization-management restrictions -- and shares fell nearly 18% the next session. NEW YORK, Aug. 14...
Ardelyx price target lowered to $11 from $14 at Citi
Citi lowered the firm’s price target on Ardelyx (ARDX) to $11 from $14 and keeps a Buy rating on the shares.
Ardelyx price target lowered to $15 from $19 at Raymond James
Raymond James lowered the firm’s price target on Ardelyx (ARDX) to $15 from $19 and keeps a Strong Buy rating on the shares. Ibsrela’s slower-than-expected trajectory suggests the thesis will…
Ardelyx price target lowered to $10 from $13 at TD Cowen
TD Cowen analyst Joseph Thome lowered the firm’s price target on Ardelyx (ARDX) to $10 from $13 and keeps a Buy rating on the shares. The firm updated its model…
Ardelyx price target lowered to $13 from $16 at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield lowered the firm’s price target on Ardelyx (ARDX) to $13 from $16 and keeps a Buy rating on the shares.
Ardelyx reports Q2 EPS (7c), consensus (5c)
Reports Q2 revenue $118.13M, consensus $121.64M. “In the second quarter of 2026, we delivered combined revenue of $118 million, up 31% year over year, the largest quarterly revenue in our…
Ardelyx Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 31% year-over-year to $118 million, with IBSRELA and XPHOZAH both achieving record demand despite payer access hurdles. Full-year guidance for IBSRELA was lowered, but profitability is expected in 2027, and the company remains focused on pipeline expansion and disciplined capital allocation.
Ardelyx Earnings release: Q2 2026
Ardelyx released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Ardelyx Quarterly report: Q2 2026
Ardelyx has published its Q2 2026 quarterly earnings report on August 6, 2026.
Ardelyx Slides: Q2 2026
Ardelyx has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercializati...
Jefferies says Ardelyx CMS appeal loss ‘shouldn’t fundamentally change anything’
Jefferies notes that an appellate court this morning reaffirmed a district court’s decision and dismissed Ardelyx’s (ARDX) appeal on Xphozah getting included in the Medicare ESRD bundle and no longer…
Ardelyx assumed with a Buy at Ladenburg
Ladenburg assumed coverage of Ardelyx (ARDX) with a Buy rating and $16 price target The company’s focus is on growing demand for Ibsrela, maintaining sales momentum for Xphozah, expanding its…
Ardelyx Transcript: Jefferies Global Healthcare Conference 2026
Management outlined strong growth for IBSRELA and XPHOZAH, with 2026 revenue expected to exceed $500 million and ambitious long-term targets of $1 billion and $750 million, respectively. Strategic investments in sales, marketing, and R&D, along with new patent protection, support confidence in sustained growth and near-term profitability.